Novel treatment for glaucoma
| Reference number | |
| Coordinator | Mim Neurosciences AB |
| Funding from Vinnova | SEK 297 000 |
| Project duration | October 2023 - October 2024 |
| Status | Ongoing |
| Venture | Innovative Startups |
| Call | Innovative Impact Startups autumn 2023 |
Purpose and goal
Mim Neurosciences is developing new drugs for neurodegenerative disease based on NAD biology. In parallel with the ongoing research and development work, the prerequisites for commercial development need to be put in place including business strategy and plans / protocols for preclinical and clinical development as well as additional intellectual property rights protection. The overall aim of this Vinnova funded project is to develop a full business, intellectual property, and clinical translational plan.
Expected results and effects
1. Development of a business plan that leads from current status to application for an IND 2. Networking with existing and new business and pharma contacts 3. Development of a website, communication materials, etc. 4. Development of an IP strategy post-PCT submission in February 2024
Planned approach and implementation
1. Strengthen the company´s management and business skills: recruit/engage relevant skills 2. Ensure continued funding: maintain existing investor contacts through regular information on progress in the projects etc. 3. Develop the business plan: consultancy to develop clinical development plans increase the potential for investment 4. Increase the awareness of Mim Neuroscience: develop a website, produce communication materials 5. IP strategy: legal consultancy for initial IP inventory and strategy